ASIF HABIB: Open Payments
NPI 1124000104 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,047 in 54 payments from 9 companies in 2025. Trend: 2023 $1,870 · 2024 $1,605 · 2025 $1,047
Food & beverage: $1,047
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $226 |
| ABBVIE INC. | 6 | $167 |
| Alkermes, Inc. | 8 | $147 |
| Otsuka America Pharmaceutical, Inc. | 8 | $145 |
| Lundbeck LLC | 9 | $140 |
| E.R. Squibb & Sons, L.L.C. | 5 | $109 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $25 |
Products named: REXULTI, CAPLYTA, VRAYLAR, ARISTADA, COBENFY, UZEDY, FANAPT, Auvelity.
Industry payments across MO — which companies pay providers there.
